The trial achieved its primary endpoint of significantly reducing pain intensity compared to placebo. The study’s results demonstrated a strong pain relief of 1.34 mean hourly difference from placebo ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine) 50 milligram oral tablets ... ibuprofen for additional pain relief as needed.